Daebong Life Science to Showcase Innovative API Developments at CPhI Frankfurt 2025

Daebong LS is pleased to announce its participation in CPhI Frankfurt 2025 on October 28th, where the company will engage in a series of B2B meetings with global partners.

During the event, Daebong LS will highlight its latest research achievements, including:
Efinaconazole Co-crystal
L-Erdosteine
Novel Salt of Azilsartan

Through these presentations, Daebong LS aims to explore opportunities for technology transfer and strengthen collaborations with leading companies in the pharmaceutical industry.

As an active developer of innovative active pharmaceutical ingredients (APIs), Daebong continues to expand its global partnerships and contribute to advancing healthcare solutions.

Please refer to the Products